Physician profile
Carrie Byrd
NPI 1073905774
$2,741.38
in general payments reported to CMS, 2019-2025
19 companies · $609 in 2025
The $609 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $775 · 2022: $842 · 2023: $231 · 2024: $285 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.19 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $873.66 | 2021-2025 | |
| Janssen Biotech, INC. | $427.92 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $352.17 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $217.66 | 2021-2023 | |
| Genzyme Corporation | $195.87 | 2022-2025 | |
| Ucb, INC. | $132.80 | 2021-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $115.00 | 2021 | |
| Galderma Laboratories, L.P. | $104.22 | 2021-2025 | Aklief, Nemluvio |
| Medtronic, INC. | $75.48 | 2021 | |
| Pfizer INC. | $64.16 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $38.13 | 2022-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $32.13 | 2025 | Dupixent |
| Paratek Pharmaceuticals, INC. | $18.41 | 2025 | Nuzyra |
| Amgen INC. | $18.31 | 2023 | Otezla |
| Cipher Pharmaceuticals US LLC | $16.51 | 2025 | Spinosad, Natroba |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $16.04 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.49 | 2023 | Spevigo |
| Sun Pharmaceutical Industries INC. | $15.48 | 2022 | |
| Dermira, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.